Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Famulla, S; Pieber, TR; Eilbracht, J; Neubacher, D; Soleymanlou, N; Woerle, HJ; Broedl, UC; Kaspers, S.
Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
Diabetes Technol Ther. 2017; 19(1):49-60
Doi: 10.1089/dia.2016.0261
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Pieber Thomas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We evaluated the effect of empagliflozin as adjunct to insulin on 24-h glucose exposure and variability in patients with type 1 diabetes. Patients (N = 75) with HbA1c ≥7.5% to ≤10.5% were randomized to receive empagliflozin 2.5 mg, empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily as adjunct to insulin for 4 weeks. Insulin dose was to be kept as stable as possible during week 1 of treatment and was freely adjustable thereafter. Markers of glucose exposure and variability were assessed from 7-day blinded continuous glucose monitoring intervals. This study is completed ( ClinicalTrials.gov NCT01969747). Empagliflozin reduced hourly mean glucose area under the median curve over 24 h versus placebo within week 1 (adjusted mean differences: -12.2 mg/dL·h [95% confidence interval -23.9 to -0.5], -30.2 mg/dL·h [-42.2 to -18.2], and -33.0 mg/dL·h [-44.8 to -21.1] with empagliflozin 2.5, 10, and 25 mg, respectively; all P < 0.05) and increased time in glucose target range (>70 to ≤180 mg/dL). Results were sustained to week 4 with empagliflozin 25 mg. All empagliflozin doses significantly reduced glucose variability (interquartile range and mean amplitude of glucose excursions) versus placebo at weeks 1 and 4. Except for small increases in hours per day with glucose ≤70 mg/dL during the stable insulin period, empagliflozin did not increase time in hypoglycemia compared with placebo. In patients with type 1 diabetes, empagliflozin as adjunct to insulin decreased glucose exposure and variability and increased time in glucose target range.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Benzhydryl Compounds - therapeutic use
- Blood Glucose - analysis
- Blood Glucose Self-Monitoring -
- Diabetes Mellitus, Type 1 - blood
- Diabetes Mellitus, Type 1 - drug therapy
- Double-Blind Method -
- Drug Therapy, Combination -
- Female -
- Glucosides - therapeutic use
- Humans -
- Hypoglycemic Agents - therapeutic use
- Insulin - therapeutic use
- Male -
- Middle Aged -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Continuous glucose monitoring
- HbA(1c)
- Hyperglycemia
- Hypoglycemia
- Postprandial blood glucose
- Type 1 diabetes